Osimertinib, also known as Tagrisso, is a targeted cancer therapy medication primarily used for the treatment of non-small cell lung cancer (NSCLC). It belongs to a class of drugs called tyrosine kinase inhibitors (TKIs) and is specifically designed to target and inhibit the activity of the EGFR (epidermal growth factor receptor) protein, which is often overexpressed in NSCLC patients. This...